ArticleInflammation2026
Genistein Has Beneficial Effects Against Non-Alcoholic Fatty Liver Disease Through Activation of the SIRT1/PPAR-α/PGC-1α and Nrf2 Signaling Pathways.
Article in Inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The development of fatty liver has been associated with hepatic metabolic derangements. Genistein has been reported to be a treatment option for Non-alcoholic fatty liver disease (NAFLD). In this study, we evaluated the effect of genistein on hepatic steatosis through the silent mating type information regulation 2 homolog - 1 (SIRT1)/peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α)/peroxisome proliferator-activated receptor α (PPARα) and Nrf2 signaling pathways in mice fed a high-fat diet (HFD). After 10 weeks of HFD feeding, the mice were randomly divided into the HFD and genistein (0.2%) groups. Genistein treatment significantly decreased liver weight and lipid accumulation in the liver of the HFD group. The mRNA level of PPARα, the acetylation of PGC-1α, mRNA, and protein levels of SIRT1 was increased in the genistein group compared with the HFD group. Genistein supplementation could enhance total antioxidant capacity, total thiol content and decrease protein carbonyl and malondialdehyde (MDA) levels in the liver of mice fed HFD. In addition, the mRNA and protein levels of Nrf2, HO-1, and SOD2 were enhanced in the liver of HFD-fed mice. These findings suggest that genistein has favorable impacts against NAFLD via activation of the SIRT1/PGC1α/PPARα and Nrf2 signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.